Caprion Receives FDA Fast Track Designation for Shigamabs Clinical Program (Business Wire via Yahoo! Finance)
MONTREAL----May 10, 2006--Caprion Pharmaceuticals Inc. announced today that the US Food and Drug Administration has granted Fast Track designation to Shigamabs, its dual antibody product being developed for the treatment of Shigatoxin-producing bacterial infections.

FDA "Shortcomings" Result From Political Neglect, Opinion Piece States (Medical News Today)
"It seems to have become great sport for public officials to revel in FDA shortcomings," and even FDA agency scientists have been "duly dismissed" in recent years when they have "sought new resources and tools" to address potential threats to the nation's food and drug supply, William Hubbard, former associate commissioner of FDA, writes in a Washington Post opinion piece... click link for more

Johnson & Johnson Now A 'Top Pick' (Forbes)
Banc of America Securities upgraded the medical device company to "buy" from "neutral."